HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/16/2013 -- Christopher & Banks Corporation (NYSE:CBK) expects to report a comparable store sales increase in the high teens for the fourth fiscal quarter as compared to the Company's previous guidance of a comparable store sales increase in the high single to low double digits. The Company also announced that it expects cash and cash equivalents at the end of the fourth fiscal quarter (February 2, 2013) to be in the range of $37 million to $38 million. Christopher & Banks Corp. traded at $6.16 up 8.6 percent during after-hours on 58350 traded shares. The retailer traded 29.50 percent above its 50-day moving average and 109.79 percent above its 200-day moving average.
Can CBK Extend Rally? Find Out Here
Novatel Wireless Inc (NASDAQ:NVTL) shares climbed 11.19% to $1.49 in the previous trading session. The 52 week trading range for the company is $1.17 – $3.69. The shares of the company plunged 50% in the last one year. The company is a provider of wireless solutions for the worldwide mobile communications markets.
Can NVTL Extend Gain? If Yes, How Far It Can Go? Find Out Here
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) on Tuesday priced a public offering of 8 million shares of its common stock at $20.13 per share. The offering is expected to close on or about January 22, 2013, subject to the satisfaction of customary closing conditions. The stock closed Tuesday's trading at $20.13, down 2.04%.
How Should Investors Trade ALNY Now? Find Out Here
Delcath Systems, Inc. (NASDAQ:DCTH) shares jumped 5.63% and closed at $1.50. The company, on Jan. 9, announced that Sky Ridge Medical Center in Lone Tree, Colo., has become the first U.S. center to initiate the Expanded Access Program (EAP), which will provide eligible patients access to treatment with the Company’s second-generation hemofiltration cartridge of its proprietary chemosaturation system. The Company’s New Drug Application (NDA) is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable metastatic ocular melanoma in the liver with a PDUFA goal date of June 15, 2013.
How Should Investors React To DCTH Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)